Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Loidi JC, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios Jefe J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Salinas NE, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Rosso RG, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Robles EM, Matteelli A, Mazza-Stalder J, Moschos C, Munoz-Torrico M, Hamdan HM, Nakčerienė B, Nicod L, Marcos MN, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Oct 10. pii: 1901522. doi: 10.1183/13993003.01522-2019. [Epub ahead of print]

PMID:
31601711
2.

Breast tuberculosis in East London: A 13-year retrospective observational study.

McGuire E, Carey L, Tiberi S, Rahman A, Jayasekera N, White V, Kunst H.

Breast J. 2019 Sep 4. doi: 10.1111/tbj.13517. [Epub ahead of print]

PMID:
31486176
3.

Management of patients with multidrug-resistant tuberculosis.

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.

PMID:
31315696
4.

Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices?

Velizarova S, Gabrovska N, Spasova A, Marais B, Harausz EP, Tiberi S, Migliori GB, Manissero D.

J Bras Pneumol. 2019 Apr 25;45(2):e20190043. doi: 10.1590/1806-3713/e20190043. English, Portuguese. No abstract available.

5.

Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation.

Tiberi S, Torrico MM, Rahman A, Krutikov M, Visca D, Silva DR, Kunst H, Migliori GB.

J Bras Pneumol. 2019 Apr 25;45(2):e20180324. doi: 10.1590/1806-3713/e20180324. Review. English, Portuguese.

6.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

7.

Necrotizing pneumonia (aetiology, clinical features and management).

Krutikov M, Rahman A, Tiberi S.

Curr Opin Pulm Med. 2019 May;25(3):225-232. doi: 10.1097/MCP.0000000000000571.

PMID:
30844921
8.

World Tuberculosis Day March 24th 2019 Theme: "It's TIME" - International Journal of Infectious Diseases Tuberculosis Theme Series.

Petersen E, Rao M, Ippolito G, Gualano G, Chakaya J, Ntoumi F, Moore D, Allen R, Gaskell K, Öhd JN, Hergens MP, Krishnamoorthy S, Ugarte-Gil C, Kirwan DE, Honeyborne I, McHugh TD, Köser CU, Kranzer K, Tiberi S, Migliori GB, Mao Q, Yang Y, Oliveira SP, Cardoso RF, Detjen A, Marais B, de Gijsel D, von Reyn CF, Goscé L, Abubakar I, Maeurer M, Zumla A.

Int J Infect Dis. 2019 Mar;80S:S1-S5. doi: 10.1016/j.ijid.2019.02.024. Epub 2019 Feb 23. No abstract available.

9.

Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study.

Sane Schepisi M, Navarra A, Altet Gomez MN, Dudnyk A, Dyrhol-Riise AM, Esteban J, Giorgetti PF, Gualano G, Guglielmetti L, Heyckendorf J, Kaluzhenina A, Lange B, Lange C, Manika K, Miah J, Nanovic Z, Pontali E, Prego MR, Solovic I, Tiberi S, Palmieri F, Girardi E.

Open Forum Infect Dis. 2018 Dec 19;6(1):ofy337. doi: 10.1093/ofid/ofy337. eCollection 2019 Jan.

10.

Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs.

Tiberi S, Pontali E, Tadolini M, D'Ambrosio L, Migliori GB.

Int J Infect Dis. 2019 Mar;80S:S68-S72. doi: 10.1016/j.ijid.2019.01.040. Epub 2019 Jan 25.

11.

Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned.

Alffenaar JC, Tiberi S, Migliori GB.

Lancet Infect Dis. 2019 Jan;19(1):3-4. doi: 10.1016/S1473-3099(18)30549-8. Epub 2018 Nov 23. No abstract available.

PMID:
30477962
12.

Bayesian inference on stochastic gene transcription from flow cytometry data.

Tiberi S, Walsh M, Cavallaro M, Hebenstreit D, Finkenstädt B.

Bioinformatics. 2018 Sep 1;34(17):i647-i655. doi: 10.1093/bioinformatics/bty568.

13.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

14.

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.

J Infect. 2019 Jan;78(1):35-39. doi: 10.1016/j.jinf.2018.08.003. Epub 2018 Aug 7.

PMID:
30096332
15.

Non-tuberculous mycobacterial pulmonary disease: a clinical update.

Rokadiya S, Millar FR, Tiberi S.

Br J Hosp Med (Lond). 2018 Aug 2;79(8):C118-C122. doi: 10.12968/hmed.2018.79.8.C118. No abstract available.

PMID:
30070955
16.

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800934. doi: 10.1183/13993003.00934-2018. Print 2018 Jul. No abstract available.

PMID:
29903862
17.

Tuberculosis elimination: where are we now?

Matteelli A, Rendon A, Tiberi S, Al-Abri S, Voniatis C, Carvalho ACC, Centis R, D'Ambrosio L, Visca D, Spanevello A, Battista Migliori G.

Eur Respir Rev. 2018 Jun 13;27(148). pii: 180035. doi: 10.1183/16000617.0035-2018. Print 2018 Jun 30. Review.

18.

QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.

Guglielmetti L, Tiberi S, Burman M, Kunst H, Wejse C, Togonidze T, Bothamley G, Lange C; TBnet; of the TBnet QTc survey.

Eur Respir J. 2018 Aug 16;52(2). pii: 1800537. doi: 10.1183/13993003.00537-2018. Print 2018 Aug. No abstract available.

PMID:
29880656
19.

Direct Whole-Genome Sequencing of Sputum Accurately Identifies Drug-Resistant Mycobacterium tuberculosis Faster than MGIT Culture Sequencing.

Doyle RM, Burgess C, Williams R, Gorton R, Booth H, Brown J, Bryant JM, Chan J, Creer D, Holdstock J, Kunst H, Lozewicz S, Platt G, Romero EY, Speight G, Tiberi S, Abubakar I, Lipman M, McHugh TD, Breuer J.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00666-18. doi: 10.1128/JCM.00666-18. Print 2018 Aug.

20.

Mycobacterium chimaera infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases.

Scriven JE, Scobie A, Verlander NQ, Houston A, Collyns T, Cajic V, Kon OM, Mitchell T, Rahama O, Robinson A, Withama S, Wilson P, Maxwell D, Agranoff D, Davies E, Llewelyn M, Soo SS, Sahota A, Cooper MA, Hunter M, Tomlins J, Tiberi S, Kendall S, Dedicoat M, Alexander E, Fenech T, Zambon M, Lamagni T, Smith EG, Chand M.

Clin Microbiol Infect. 2018 Nov;24(11):1164-1170. doi: 10.1016/j.cmi.2018.04.027. Epub 2018 May 25.

21.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. Review. Portuguese, English.

22.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
23.

A cluster of two human cases of tick-borne encephalitis (TBE) transmitted by unpasteurised goat milk and cheese in Germany, May 2016.

Brockmann SO, Oehme R, Buckenmaier T, Beer M, Jeffery-Smith A, Spannenkrebs M, Haag-Milz S, Wagner-Wiening C, Schlegel C, Fritz J, Zange S, Bestehorn M, Lindau A, Hoffmann D, Tiberi S, Mackenstedt U, Dobler G.

Euro Surveill. 2018 Apr;23(15). doi: 10.2807/1560-7917.ES.2018.23.15.17-00336.

24.

Defining the best regimen to treat isoniazid-resistant tuberculosis.

Migliori GB, Tiberi S, Sotgiu G.

Lancet Respir Med. 2018 Apr;6(4):233-235. doi: 10.1016/S2213-2600(18)30079-1. No abstract available.

PMID:
29595499
25.

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.

Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, Caws M, Tiberi S, Bolhuis M, Alffenaar JC, Davies G, Sloan DJ.

J Antimicrob Chemother. 2018 Jul 1;73(7):1755-1762. doi: 10.1093/jac/dky096.

26.

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5. Epub 2018 Mar 23. Review. Erratum in: Lancet Infect Dis. 2018 Apr 27;:.

PMID:
29580819
27.

Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!

Tiberi S, Cabibbe AM, Tomlins J, Cirillo DM, Migliori GB.

EBioMedicine. 2018 Mar;29:11-12. doi: 10.1016/j.ebiom.2018.02.006. Epub 2018 Feb 8. No abstract available.

28.

Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB".

Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-Manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, Rao M, Kapata N, Azhar EI, Memish ZA, Mfinanga S, Aseffa A, Ippolito G, Migliori GB, Zumla A.

Int J Infect Dis. 2018 Mar;68:122-124. doi: 10.1016/j.ijid.2018.03.002. Epub 2018 Mar 22. No abstract available.

29.

The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control.

Otu A, Hashmi M, Mukhtar AM, Kwizera A, Tiberi S, Macrae B, Zumla A, Dünser MW, Mer M.

J Crit Care. 2018 Jun;45:184-196. doi: 10.1016/j.jcrc.2018.03.015. Epub 2018 Mar 13. Review.

PMID:
29571116
30.

Accelerating the development of therapeutic strategies for drug-resistant tuberculosis.

Vjecha MJ, Tiberi S, Zumla A.

Nat Rev Drug Discov. 2018 Sep;17(9):607-608. doi: 10.1038/nrd.2018.28. Epub 2018 Mar 23.

PMID:
29567994
31.

Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Centis R, Alffenaar JW, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702187. doi: 10.1183/13993003.02187-2017. Print 2018 Mar. No abstract available.

32.

Single-center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients.

Veronese G, Ammirati E, Moioli MC, Baldan R, Orcese CA, De Rezende G, Veronese S, Masciocco G, Perna E, Travi G, Puoti M, Cipriani M, Tiberi S, Cirillo D, Frigerio M.

Transpl Infect Dis. 2018 Jun;20(3):e12880. doi: 10.1111/tid.12880. Epub 2018 Mar 25.

PMID:
29514393
33.

Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; for TBNET.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):379-386. doi: 10.1164/rccm.201710-2141OC.

PMID:
29509468
34.

Shigellosis and toxic megacolon secondary to Shigella flexneri serotype 3a: The challenges of laboratory diagnosis.

McGuire E, Tiberi S, Ciesielczuk H, Melzer M.

Int J Infect Dis. 2018 May;70:104-106. doi: 10.1016/j.ijid.2018.02.020. Epub 2018 Mar 2.

35.

New drugs and perspectives for new anti-tuberculosis regimens.

Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24. Review.

36.

Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.

Tadolini M, Tiberi S, Migliori GB.

Lancet Infect Dis. 2018 May;18(5):480-481. doi: 10.1016/S1473-3099(18)30106-3. Epub 2018 Feb 13. No abstract available.

PMID:
29452940
37.

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

D'Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, Payen MC, Saavedra Herrera N, Salazar Lezama MA, Skrahina A, Tadolini M, Tiberi S, Veziris N, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):132-141. doi: 10.1016/j.rppnen.2017.10.005. Epub 2017 Dec 8. Review.

38.

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.

Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701462. doi: 10.1183/13993003.01462-2017. Print 2017 Nov. No abstract available.

39.

Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?

Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Int J Infect Dis. 2017 Dec;65:133-134. doi: 10.1016/j.ijid.2017.10.019. Epub 2017 Nov 6. No abstract available.

40.

Post-implementation blues: the unfulfilled potential of Xpert.

Tiberi S, Pontali E, Migliori GB.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1073. doi: 10.5588/ijtld.17.0478. No abstract available.

PMID:
28911347
41.

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, Esposito S, Migliori GB.

J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16. Review.

42.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Emerg Infect Dis. 2017 Oct;23(10). doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

43.

Intestinal tuberculosis: a diagnostic challenge.

Kentley J, Ooi JL, Potter J, Tiberi S, O'Shaughnessy T, Langmead L, Chin Aleong J, Thaha MA, Kunst H.

Trop Med Int Health. 2017 Aug;22(8):994-999. doi: 10.1111/tmi.12908. Epub 2017 Jul 5.

44.

Treatment outcomes of MDR-TB and HIV co-infection in Europe.

Magis-Escurra C, Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBnet.

Eur Respir J. 2017 Jun 8;49(6). pii: 1602363. doi: 10.1183/13993003.02363-2016. Print 2017 Jun. No abstract available.

45.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

46.

A composite likelihood approach to predict the sex of the baby.

Tiberi S, Scarpa B, Sartori N.

Stat Methods Med Res. 2018 Nov;27(11):3386-3396. doi: 10.1177/0962280217702415. Epub 2017 Apr 10.

PMID:
28395600
47.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
48.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

49.

Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.

Dedicoat MJ, Günther G, Crudu V, Duarte R, Gualano G, Magis-Escurra C, Rumetshofer R, Skrahina A, Spinu V, Tiberi S, Viiklepp P, van Leth F, Lange C; for TBNET ‡.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1222-1224. doi: 10.1164/rccm.201612-2585LE. No abstract available.

PMID:
28323453
50.

The challenge of the new tuberculosis drugs.

Tiberi S, Buchanan R, Caminero JA, Centis R, Arbex MA, Salazar M, Potter J, Migliori GB.

Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28. Review. French.

PMID:
28256383

Supplemental Content

Loading ...
Support Center